GR3007434T3 - - Google Patents

Info

Publication number
GR3007434T3
GR3007434T3 GR930400621T GR930400621T GR3007434T3 GR 3007434 T3 GR3007434 T3 GR 3007434T3 GR 930400621 T GR930400621 T GR 930400621T GR 930400621 T GR930400621 T GR 930400621T GR 3007434 T3 GR3007434 T3 GR 3007434T3
Authority
GR
Greece
Application number
GR930400621T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26290693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3007434(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3007434T3 publication Critical patent/GR3007434T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR930400621T 1986-04-30 1993-03-23 GR3007434T3 (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB08610572A GB2189698A (en) 1986-04-30 1986-04-30 Coated omeprazole tablets
SG154294A SG154294G (en) 1986-04-30 1994-10-21 New pharmaceutical preparation for oral use

Publications (1)

Publication Number Publication Date
GR3007434T3 true GR3007434T3 (enEXAMPLES) 1993-07-30

Family

ID=26290693

Family Applications (4)

Application Number Title Priority Date Filing Date
GR89300058T GR890300058T1 (en) 1986-04-30 1989-06-22 New pharmaceutical preparation for oral use
GR930400621T GR3007434T3 (enEXAMPLES) 1986-04-30 1993-03-23
GR960402099T GR3020734T3 (en) 1986-04-30 1996-08-07 Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
GR990403191T GR3032101T3 (en) 1986-04-30 1999-12-10 Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR89300058T GR890300058T1 (en) 1986-04-30 1989-06-22 New pharmaceutical preparation for oral use

Family Applications After (2)

Application Number Title Priority Date Filing Date
GR960402099T GR3020734T3 (en) 1986-04-30 1996-08-07 Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
GR990403191T GR3032101T3 (en) 1986-04-30 1999-12-10 Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

Country Status (35)

Country Link
US (1) US4786505A (enEXAMPLES)
EP (3) EP0247983B1 (enEXAMPLES)
JP (2) JPS62258320A (enEXAMPLES)
KR (1) KR910004579B1 (enEXAMPLES)
CN (1) CN1020852C (enEXAMPLES)
AR (1) AR240250A1 (enEXAMPLES)
AT (3) ATE140387T1 (enEXAMPLES)
CA (1) CA1292693C (enEXAMPLES)
CY (1) CY1810A (enEXAMPLES)
DD (1) DD273197A5 (enEXAMPLES)
DE (3) DE3751860T2 (enEXAMPLES)
DK (1) DK169988B1 (enEXAMPLES)
DZ (1) DZ1077A1 (enEXAMPLES)
ES (3) ES2135443T3 (enEXAMPLES)
FI (1) FI90393C (enEXAMPLES)
GB (1) GB2189698A (enEXAMPLES)
GR (4) GR890300058T1 (enEXAMPLES)
HK (2) HK135294A (enEXAMPLES)
HR (1) HRP920854B1 (enEXAMPLES)
HU (1) HU196708B (enEXAMPLES)
IE (1) IE61416B1 (enEXAMPLES)
IL (1) IL82911A (enEXAMPLES)
IS (1) IS1917B (enEXAMPLES)
LT (1) LT3699B (enEXAMPLES)
LV (2) LV10357B (enEXAMPLES)
NO (1) NO174239C (enEXAMPLES)
NZ (1) NZ220096A (enEXAMPLES)
PH (1) PH25701A (enEXAMPLES)
PL (1) PL151631B1 (enEXAMPLES)
PT (1) PT84785B (enEXAMPLES)
RU (2) RU1820837C (enEXAMPLES)
SG (1) SG154294G (enEXAMPLES)
SI (1) SI8710681A8 (enEXAMPLES)
YU (1) YU46192B (enEXAMPLES)
ZA (1) ZA872378B (enEXAMPLES)

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JPH0737383B2 (ja) * 1988-07-11 1995-04-26 エーザイ株式会社 胃酸分泌抑制剤含有固型製剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
ATE109973T1 (de) * 1989-05-11 1994-09-15 Chugai Pharmaceutical Co Ltd Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
GB9223702D0 (en) 1992-11-12 1992-12-23 Lucas Ind Plc Improvements in hydraulic braking systems for vehicles
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
TW397686B (en) * 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
TW280770B (enEXAMPLES) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1995018612A1 (en) * 1994-01-05 1995-07-13 Aktiebolaget Astra A method for treatment of psoriasis, by omeprazole or related compounds
DK0746310T3 (da) * 1994-02-23 1999-08-02 Bm Res As Præparat med styret afgivelse
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
DK0793691T3 (da) * 1994-11-21 1999-02-15 Shell Int Research Bitumenkompositioner
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
GB2316342B (en) * 1995-05-09 2000-01-12 Colorcon Ltd Electrostatic coating
US7008668B2 (en) 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
CZ352097A3 (cs) * 1995-05-09 1998-04-15 Colorcon Limited Způsob a materiál pro elektrostatické potahování jádra farmaceutických tablet
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
ES2201200T3 (es) * 1995-09-21 2004-03-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil al acido, y procedimiento para su preparacion.
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
AU5179898A (en) * 1996-11-06 1998-05-29 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) * 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
ATE260090T1 (de) * 1997-12-08 2004-03-15 Altana Pharma Ag Neue suppositoriumsform mit säureempfindliche wirkstoffe
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
AU770633B2 (en) * 1998-11-18 2004-02-26 Astrazeneca Ab Improved chemical process and pharmaceutical formulation
RU2144823C1 (ru) * 1998-11-20 2000-01-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Лекарственное средство, обладающее слабительным действием
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
ATE369857T1 (de) 1999-10-20 2007-09-15 Eisai R&D Man Co Ltd Methode zur stabilisierung von benzimidazol- verbindungen
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
GB0002305D0 (en) 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CA2448927C (en) 2001-05-30 2011-08-09 Euro-Celtique, S.A. Pharmaceutical composition
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2163241A1 (en) * 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
ATE507823T1 (de) 2001-09-28 2011-05-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
CA2463690C (en) * 2001-10-17 2011-08-23 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ATE363480T1 (de) 2002-03-05 2007-06-15 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AU2003209534A1 (en) * 2002-03-08 2003-09-22 Bakulesh Mafatlal Khamar The method of treating tuberculosis
US20030180358A1 (en) * 2002-03-25 2003-09-25 Stumberger Walter William System and method for affecting the pH state of the contents of the distal bowel in mammals
US20050182100A1 (en) * 2002-03-28 2005-08-18 Ola Junghard Method of use
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
ES2299710T3 (es) * 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20070036851A1 (en) * 2002-12-23 2007-02-15 Deepak Thassu Acid labile drug compositions
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
EP1602362B1 (en) 2003-03-12 2016-09-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
EP1617842A1 (en) * 2003-04-22 2006-01-25 Dr. Reddy's Laboratories Ltd. Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
GB2420298B (en) * 2003-06-18 2006-08-23 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
BRPI0412697A (pt) * 2003-07-17 2006-10-03 Reddys Lab Inc Dr composições farmacêuticas que apresentam um revestimento expansìvel
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
CA2536902A1 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
JP2007505921A (ja) * 2003-09-19 2007-03-15 ペンウェスト ファーマシューティカルズ カンパニー 遅延放出剤形
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) * 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
CN1898569A (zh) * 2003-10-24 2007-01-17 伊缪因艾德有限公司 治疗方法
EP1677770A2 (en) * 2003-10-31 2006-07-12 Dexcel Ltd. Stable lansoprazole formulation
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20070141137A1 (en) * 2004-03-04 2007-06-21 Naoki Nagahara Stable capsule preparation
ATE407693T1 (de) * 2004-03-22 2008-09-15 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin,mit tensiden
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
JP2008500365A (ja) * 2004-05-25 2008-01-10 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにその製造方法および使用方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
WO2006002077A2 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EA012982B1 (ru) * 2004-09-20 2010-02-26 Лтб4 Свиден Аб Стабилизированная фармацевтическая композиция лейкотриен в(ltb) агента
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1833469A2 (en) * 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007014896A1 (en) * 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
EP1931316B2 (en) * 2005-08-15 2017-02-22 Abbott Laboratories GmbH Controlled release pharmaceutical compositions for acid labile drugs
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
AU2006323245B2 (en) 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090104264A1 (en) * 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
EP1973532A1 (en) * 2006-01-16 2008-10-01 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
CN101410094B (zh) * 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
ES2533563T5 (es) 2006-01-27 2018-07-24 Adare Pharmaceuticals, Inc. Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos
WO2007090113A2 (en) 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
CA2647497C (en) 2006-04-04 2016-01-12 Cogentus Pharmaceuticals, Inc. Oral dosage forms including an antiplatelet agent and an acid inhibitor
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
JP5474541B2 (ja) 2006-07-25 2014-04-16 ベクタ・リミテッド 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
AU2007311493B2 (en) * 2006-10-17 2013-01-31 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
CN101663027B (zh) * 2007-05-07 2013-02-27 赢创罗姆有限责任公司 包含肠溶包衣的可促进药物释放的固体剂型
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
KR20150084013A (ko) 2007-10-12 2015-07-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE AND BUFFER AGENTS AND METHOD OF USE
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
CA2728547A1 (en) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Solid dosage formulations of telcagepant potassium
CA2724533C (en) * 2008-07-24 2014-07-29 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
JP2011530569A (ja) * 2008-08-11 2011-12-22 メファ・ゲーエムベーハー 特定の分離層を含むオメプラゾールの経口医薬製剤
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
GB2480042B (en) 2009-02-24 2014-03-12 Ritter Pharmaceuticals Inc Solid oral unit-dosage prebiotic forms and methods of use
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
ES2515715T5 (es) 2010-10-01 2021-06-22 Nestle Sa Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
ES2673286T3 (es) 2011-02-11 2018-06-21 Zx Pharma, Llc Formulaciones multiparticuladas de L-mentol y métodos relacionados
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
GB201117480D0 (en) * 2011-10-10 2011-11-23 Palikaras George Filter
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
BR112015002309A2 (pt) 2012-08-07 2017-07-04 Buck Inst Res Aging formulação de múltiplos componentes para aprimorar a função neurológica
CN102940611B (zh) * 2012-11-26 2017-02-22 康普药业股份有限公司 一种含有埃索美拉唑镁的肠溶片剂
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
BR112015016917B1 (pt) 2013-01-15 2022-08-30 Ironwood Pharmaceuticals, Inc Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
WO2014136494A1 (ja) * 2013-03-08 2014-09-12 富士フイルム株式会社 腸溶性細粒及び医薬組成物
HUE042996T2 (hu) 2013-04-23 2019-07-29 Zx Pharma Llc Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény
KR20160087794A (ko) 2013-08-09 2016-07-22 앨러간 파마슈티컬스 인터내셔널 리미티드 장관 투여에 적합한 소화 효소 조성물
CA2932662A1 (en) * 2013-12-20 2015-06-25 9286-3620 Quebec Inc. Protein-based enteric coating for oral dosage forms
CN104490840B (zh) * 2013-12-30 2018-09-28 成都迪康药业股份有限公司 泮托拉唑钠肠溶制剂及其制备方法
CN104337788B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 埃索美拉唑钠肠溶制剂及其制备方法
CN104337789B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 雷贝拉唑钠肠溶制剂及其制备方法
KR101658275B1 (ko) 2014-01-20 2016-09-20 대원제약주식회사 에스오메프라졸 함유 소형 의약정제
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
DK3324948T3 (da) * 2015-07-17 2023-05-08 Be Pharbel Mfg Flerlagsmikropartikler til frigivelse af en farmaceutisk aktiv forbindelse i en flydende doseringsform
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US20190240187A1 (en) * 2015-11-27 2019-08-08 Symrise Ag Oral preparations with omeprazole or pantoprazole
KR102408525B1 (ko) 2016-01-08 2022-06-13 더 리전트 오브 더 유니버시티 오브 캘리포니아 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
EP3455223B1 (en) 2016-05-12 2023-11-08 Buck Institute for Research on Aging Compounds to promote normal processing of app
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
WO2018183881A1 (en) * 2017-03-31 2018-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2018236955A1 (en) 2017-06-23 2018-12-27 The Regents Of The University Of California IMPROVING GABA CAPACITY TO MODULATE IMMUNE RESPONSES
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3735250A4 (en) 2018-01-01 2022-04-13 The Regents Of The University Of California INDUSTRIAL-SCALE SYNTHESIS OF SILICASOMES-TYPE NANOSUPPORTS
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
RU2694527C1 (ru) 2018-02-06 2019-07-16 Шмуэль Борис Левит Комбинация для регенеративной терапии больных сахарным диабетом 1 типа
EP3610860A1 (en) * 2018-08-15 2020-02-19 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Composition of carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose
KR102146395B1 (ko) 2018-08-23 2020-08-20 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113766916B (zh) 2019-01-22 2024-04-05 艾奥维安制药公司 Mtorc调节剂及其用途
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
TW202126301A (zh) 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
EP4072532B1 (en) * 2019-12-11 2024-01-24 Evonik Operations GmbH Dosage form for use in treating or preventing of a disease
IL293651A (en) * 2019-12-11 2022-08-01 Evonik Operations Gmbh Dosage form comprising an alkaline agent and an enteric coating layer
CA3160862A1 (en) * 2019-12-11 2021-06-17 Priyanka HAKSAR Dosage form for use in treating or preventing of a disease
CN114569579B (zh) * 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN114569580B (zh) * 2020-12-02 2024-03-01 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN112919975B (zh) * 2021-04-01 2022-02-11 山东爱福地生物股份有限公司 一种智能调控土壤酸碱度的有机肥的生产工艺
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
JP2025509208A (ja) 2022-03-04 2025-04-11 レバジェニックス・インコーポレーテッド 広域スペクトルアミノグリコシド及びその使用
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
DE1617615A1 (de) * 1966-05-03 1971-03-25 Merck Patent Gmbh Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4382091A (en) * 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
AU571312B2 (en) * 1984-02-10 1988-04-14 Nycomed Danmark A/S Diffusion coated multiple-units dosage form
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685919A (en) * 1985-03-14 1987-08-11 Ngk Spark Plug Co., Ltd. Artificial joint
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物

Also Published As

Publication number Publication date
PT84785A (en) 1987-05-01
HU196708B (en) 1989-01-30
LV5760B4 (lv) 1997-06-20
DK215887A (da) 1987-10-31
JP5069807B2 (enEXAMPLES) 1993-10-01
ATE140387T1 (de) 1996-08-15
GR3032101T3 (en) 2000-03-31
DK215887D0 (da) 1987-04-28
ES2006457T3 (es) 1994-01-01
ZA872378B (en) 1987-12-30
NZ220096A (en) 1990-04-26
ES2135443T3 (es) 1999-11-01
HK135294A (en) 1994-12-09
DD273197A5 (de) 1989-11-08
NO871790D0 (no) 1987-04-29
LV10357A (lv) 1995-02-20
YU46192B (sh) 1993-05-28
EP0496437B1 (en) 1996-07-17
HRP920854A2 (en) 1994-10-31
SI8710681A8 (en) 1996-10-31
US4786505A (en) 1988-11-22
FI90393B (fi) 1993-10-29
JPS62258320A (ja) 1987-11-10
HRP920854B1 (en) 1998-12-31
CA1292693C (en) 1991-12-03
CN87103284A (zh) 1987-11-11
IS3221A7 (is) 1987-10-31
GR890300058T1 (en) 1989-06-22
LV5760A4 (lv) 1996-12-20
HUT43954A (en) 1988-01-28
PH25701A (en) 1991-09-18
DZ1077A1 (fr) 2004-09-13
DE3751860D1 (de) 1996-08-22
EP0496437A3 (en) 1992-09-02
LV10357B (en) 1996-04-20
LT3699B (en) 1996-02-26
GB8610572D0 (en) 1986-06-04
RU2095054C1 (ru) 1997-11-10
ATE84215T1 (de) 1993-01-15
ES2091971T3 (es) 1996-11-16
EP0247983A3 (en) 1988-10-19
JPH05294831A (ja) 1993-11-09
GB2189698A (en) 1987-11-04
YU68187A (en) 1988-12-31
FI871913A0 (fi) 1987-04-29
NO174239C (no) 1994-04-06
CN1020852C (zh) 1993-05-26
IE61416B1 (en) 1994-11-02
EP0567201A2 (en) 1993-10-27
EP0496437A2 (en) 1992-07-29
DK169988B1 (da) 1995-04-24
FI871913L (fi) 1987-10-31
DE3751860T2 (de) 1996-11-21
FI90393C (sv) 1994-02-10
DE247983T1 (de) 1990-09-27
EP0567201A3 (en) 1995-06-07
AR240250A1 (es) 1990-03-30
IE871107L (en) 1987-10-30
EP0247983B1 (en) 1993-01-07
DE3783394T2 (de) 1993-05-06
EP0247983A2 (en) 1987-12-02
ES2006457A4 (es) 1989-05-01
NO871790L (no) 1987-11-02
RU1820837C (ru) 1993-06-07
JP2740993B2 (ja) 1998-04-15
GR3020734T3 (en) 1996-11-30
AU601974B2 (en) 1990-09-27
KR870009717A (ko) 1987-11-30
PL151631B1 (en) 1990-09-28
KR910004579B1 (ko) 1991-07-06
SG154294G (en) 1995-03-17
EP0567201B1 (en) 1999-09-15
AU7191287A (en) 1987-11-05
DE3783394D1 (de) 1993-02-18
HK52897A (en) 1997-05-02
NO174239B (no) 1993-12-27
PT84785B (pt) 1989-12-29
IS1917B (is) 2004-03-15
IL82911A (en) 1991-06-30
PL265416A1 (en) 1988-07-21
CY1810A (en) 1995-10-20
LTIP1683A (en) 1995-07-25
ATE184482T1 (de) 1999-10-15

Similar Documents

Publication Publication Date Title
AU7131891A (enEXAMPLES)
CH667770GA3 (enEXAMPLES)
AU7354491A (enEXAMPLES)
AU6562586A (enEXAMPLES)
IN166617B (enEXAMPLES)
AU5940986A (enEXAMPLES)
AU5684886A (enEXAMPLES)
AU5173485A (enEXAMPLES)
AU5227086A (enEXAMPLES)
AU5257190A (enEXAMPLES)
AU5329886A (enEXAMPLES)
AU5344086A (enEXAMPLES)
AU5348186A (enEXAMPLES)
AU5444986A (enEXAMPLES)
AU5480786A (enEXAMPLES)
AU5537386A (enEXAMPLES)
AU5558386A (enEXAMPLES)
AU5614486A (enEXAMPLES)
AU6053586A (enEXAMPLES)
AU5655786A (enEXAMPLES)
AU6019186A (enEXAMPLES)
AU5703286A (enEXAMPLES)
AU5745586A (enEXAMPLES)
AU5783386A (enEXAMPLES)
AU4946385A (enEXAMPLES)